Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by IMPACT Medicom. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by IMPACT Medicom or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Management of Peripheral Neuropathy Associated with Brentuximab Vedotin in cHL

19:42
 
Share
 

Manage episode 473597555 series 2812899
Content provided by IMPACT Medicom. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by IMPACT Medicom or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this podcast episode, Dr. Michael Chu discusses the management of peripheral neuropathy associated with the use of brentuximab vedotin for the first-line treatment of classical Hodgkin Lymphoma.
Our Guest
Dr. Michael Chu is a clinician scientist at the Cross Cancer Institute and an Associate Professor at the University of Alberta in Edmonton, Alberta.
This podcast episode was sponsored by Pfizer Canada Inc.
If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).

  continue reading

70 episodes

Artwork
iconShare
 
Manage episode 473597555 series 2812899
Content provided by IMPACT Medicom. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by IMPACT Medicom or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this podcast episode, Dr. Michael Chu discusses the management of peripheral neuropathy associated with the use of brentuximab vedotin for the first-line treatment of classical Hodgkin Lymphoma.
Our Guest
Dr. Michael Chu is a clinician scientist at the Cross Cancer Institute and an Associate Professor at the University of Alberta in Edmonton, Alberta.
This podcast episode was sponsored by Pfizer Canada Inc.
If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).

  continue reading

70 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play